Beta Bionics, Inc.

BBNX Healthcare Medical Devices

Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.8%, EPS fell 35.9% and free cash flow fell 1.87%, each against the same quarter a year earlier.

16.35 0.96 −5.55%
Market cap
$933.8M
P/E
0.0×
Fwd P/E
−6.3×
Dividend yield
—
F-score
5/9
Altman Z
16.89
Beneish M
−1.86
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
231.03 247.99 267.91 270.03
Total non-current assets
61.35 56.43 60.84 60.02
Total Assets
292.39 304.42 328.74 330.05
Total current liabilities
26.02 23.19 30.92 25.39
Total non-current liabilities
10.00 9.98 10.21 9.90
Total liabilities
36.02 33.17 41.13 35.29
Common Equity (Total)
256.37 271.25 287.61 294.76
Shareholders Equity (Total)
256.37 271.25 287.61 294.76

Show all line items

In millions of $ except per-share values · columns are period end dates